ADIPOQ and breast cancer: When these values are juxtaposed to the 15.5 μg/mL plasma concentration of adiponectin below which breast cancer survival has been reported to be adversely affected (above the median: 15.5 μg/mL, longer breast cancer survival, HR, 0.39; 95% CI, 0.15 to 0.95, [74]), it would seem premature to consider adiponectin of value in assessing prognosis for survival benefit, particularly in the weight loss setting.